Clinical Trials
6 trialsNCT05618613 2025-05-09
ELONA
Context Therapeutics Inc.
Phase 1/2 Terminated
NCT06938711 2025-04-22
A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer
Context Therapeutics Inc.
Phase 1/2 Withdrawn
NCT04738292 2024-05-03
Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)
University of Wisconsin, Madison
Phase 2 Terminated
NCT04142892 2022-04-01
ONAWA
SOLTI Breast Cancer Research Group
Phase EARLY_PHASE1 Completed
NCT02049190 2015-06-24
Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer
Arno Therapeutics
Phase 1/2 Unknown
NCT02052128 2015-06-24
Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers
Arno Therapeutics
Phase 1/2 Unknown